Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin
- PMID: 2499339
- DOI: 10.1016/0006-2952(89)90306-7
Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin
Abstract
We have examined the effect of the oral gold compound auranofin (AF) on calcium ionophore A23187-induced arachidonic acid metabolism in the rat alveolar macrophage. Both reverse-phase high performance liquid chromatographic and radioimmunoassay analyses revealed that AF dose-dependently inhibited leukotriene B4 and 5-hydroxyeicosatetraenoic acid synthesis in a parallel fashion with an IC50 approximately 4.3 micrograms/ml. At the same time, AF augmented A23187-induced arachidonate release and cyclooxygenase metabolism. A possible mechanism for the inhibition of 5-lipoxygenase was suggested by the capacity of AF to dose-dependently deplete ATP (IC50 approximately 5.9 micrograms/ml), a cofactor for 5-lipoxygenase. These data indicate that, at therapeutic concentrations, AF acts in vitro as a selective inhibitor of macrophage 5-lipoxygenase metabolism. This likely represents an important mechanism of action of AF in chronic inflammatory disorders.
Similar articles
-
Hydrogen peroxide inhibits alveolar macrophage 5-lipoxygenase metabolism in association with depletion of ATP.J Biol Chem. 1988 Oct 15;263(29):14776-83. J Biol Chem. 1988. PMID: 2844785
-
Inhibitory effect of exogenous arachidonic acid on alveolar macrophage 5-lipoxygenase metabolism. Role of ATP depletion.J Immunol. 1988 Mar 15;140(6):1958-66. J Immunol. 1988. PMID: 3126237
-
Modulation of alveolar macrophage-derived 5-lipoxygenase products by the sulfhydryl reactant, N-ethylmaleimide.J Biol Chem. 1987 Aug 5;262(22):10594-600. J Biol Chem. 1987. PMID: 3112148
-
The effects of a novel series of selective inhibitors of arachidonate 5-lipoxygenase on anaphylactic and inflammatory responses.Ann N Y Acad Sci. 1988;524:307-20. doi: 10.1111/j.1749-6632.1988.tb38554.x. Ann N Y Acad Sci. 1988. PMID: 2837965 Review.
-
Review: lipoxygenase inhibitors and the gut.Aliment Pharmacol Ther. 1987 Aug;1(4):263-72. doi: 10.1111/j.1365-2036.1987.tb00626.x. Aliment Pharmacol Ther. 1987. PMID: 2979671 Review.
Cited by
-
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Oncotarget. 2014 Sep 30;5(18):8052-82. doi: 10.18632/oncotarget.2408. Oncotarget. 2014. PMID: 25211298 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources